- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Feb 16, 2004
Clinical News
Humira adalimumab: Phase II; marketed for rheumatoid arthritis (RA) in
BioCentury | Feb 9, 2004
Clinical News
Humira adalimumab: Phase III; marketed to treat rheumatoid arthritis (RA)
BioCentury | Oct 13, 2003
Clinical News
Humira adalimumab: Phase III; marketed for rheumatoid arthritis (RA)
BioCentury | Oct 6, 2003
Clinical News
Humira adalimumab: Phase III; marketed for rheumatoid arthritis (RA)
Items per page:
1 - 10 of 90